Novel anti-inflammatory therapy for Parkinson's disease

Trends in Pharmacological Sciences

Volumn 24, Issue 8, 2003, Pages 395-401

  Gao, Hui Ming ^a   Liu, Bin ^a   Zhang, Wangqin ^a   Hong, Jau Shyong ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2 INHIBITOR; DEXTROMETHORPHAN; DOPAMINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; LEVODOPA; LIPOPOLYSACCHARIDE; MINOCYCLINE; NALOXONE; NONSTEROID ANTIINFLAMMATORY AGENT; PESTICIDE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROTENONE; SALICYLATE SODIUM; SILYMARIN; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANTIINFLAMMATORY ACTIVITY; CELL LOSS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENVIRONMENTAL FACTOR; INHIBITION KINETICS; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYMPTOM; TREATMENT OUTCOME;

EID: 0043162103     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(03)00176-7     Document Type: Article

References (66)

1. Langston J.W., et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46:1999;598-605.
2. McGeer P.L., et al. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 38:1988;1285-1291.
3. Liberatore G.T., et al. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5:1999;1403-1409.
4. Sriram K., et al. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J. 16:2002;1474-1476.
5. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19:1996;312-318.
6. Gao H.M., et al. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 22:2002;782-790.
7. Cicchetti F., et al. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur. J. Neurosci. 15:2002;991-998.
8. Castano A., et al. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J. Neurochem. 70:1998;1584-1592.
9. Kim W.G., et al. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 20:2000;6309-6316.
10. Herrera A.J., et al. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol. Dis. 7:2000;429-447.
11. Liu B., et al. Systemic infusion of naloxone reduces degeneration of rat substantia nigral dopaminergic neurons induced by intranigral injection of lipopolysaccharide. J. Pharmacol. Exp. Ther. 295:2000;125-132.
12. Wu D.C., et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Neurosci. 22:2002;1763-1771.
13. Du Y., et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98:2001;14669-14674.
14. Teismann P., Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse. 39:2001;167-174.
15. He Y., et al. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 909:2001;187-193.
16. Wyss-Coray T., Mucke L. Inflammation in neurodegenerative disease - a double-edged sword. Neuron. 35:2002;419-432.
17. Compston A. Brain repair. J. Intern. Med. 237:1995;127-134.
18. Klocker N., Bahr M. Brain repair-new avenues to an eternal dream? Trends Neurosci. 24:2001;3-4.
19. Carson M.J., Sutcliffe J.G. Balancing function versus self defense: the CNS as an active regulator of immune responses. J. Neurosci. Res. 55:1999;1-8.
20. Vila M., et al. The role of glial cells in Parkinson's disease. Curr. Opin. Neurol. 14:2001;483-489.
21. Liu B., Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 304:2003;1-7.
22. Merrill J.E., Benveniste E.N. Cytokines in inflammatory brain lesions: helpful and harmful. Trends Neurosci. 19:1996;331-338.
23. Koutsilieri E., et al. Degeneration of neuronal cells due to oxidative stress-microglial contribution. Parkinsonism Relat. Disord. 8:2002;401-406.
24. Gao H.M., et al. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 81:2002;1285-1297.
25. Gao, H.M. et al. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. (in press).
26. Wu D.C., et al. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 100:2003;6145-6150.
27. Gao, H.M. et al. Critical role of microglial NADPH oxidase-derived free radicals in the MPTP model of parkinson's disease. FASEB J. (in press).
28. Gao H.M., et al. Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of parkinson's disease. J. Neurosci. 23:2003;1228-1236.
29. Dehmer T., et al. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 74:2000;2213-2216.
30. Lawson L.J., et al. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience. 39:1990;151-170.
31. Gayle D.A., et al. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res. Dev. Brain Res. 133:2002;27-35.
32. McNaught K.S., Jenner P. Dysfunction of rat forebrain astrocytes in culture alters cytokine and neurotrophic factor release. Neurosci. Lett. 285:2000;61-65.
33. Parish C.L., et al. The role of interleukin-1, interleukin-6, and glia in inducing growth of neuronal terminal arbors in mice. J. Neurosci. 22:2002;8034-8041.
34. Bolin L.M., et al. Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice. J. Neurochem. 83:2002;167-175.
35. Saura J., et al. Intranigral infusion of interleukin-1beta activates astrocytes and protects from subsequent 6-hydroxydopamine neurotoxicity. J. Neurochem. 85:2003;651-661.
36. Rousselet E., et al. Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP. Exp. Neurol. 177:2002;183-192.
37. Batchelor P.E., et al. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J. Neurosci. 19:1999;1708-1716.
38. Dong Y., Benveniste E.N. Immune function of astrocytes. Glia. 36:2001;180-190.
39. Kordower J.H. In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease. Ann Neurol. 53:(Suppl. 3):2003;S120-S132.
40. Gill S.S., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9:2003;589-595.
41. Beal M.F. Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2:2001;325-334.
42. Feng Z.H., et al. Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci. Lett. 329:2002;354-358.
43. Betarbet R., et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3:2000;1301-1306.
44. Sherer T.B., et al. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci. Lett. 341:2003;87-90.
45. Mogi M., et al. Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha induction. Neurosci. Lett. 268:1999;101-104.
46. Kurkowska-Jastrzebska I., et al. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse. Exp. Neurol. 156:1999;50-61.
47. Castano A., et al. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J. Neurochem. 81:2002;150-157.
48. Aubin N., et al. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J. Neurochem. 71:1998;1635-1642.
49. Sairam K., et al. Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res. 966:2003;245-252.
50. Teismann P., et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 100:2003;5473-5478.
51. Araki E., et al. Cyclooxygenase-2 inhibitor ns-398 protects neuronal cultures from lipopolysaccharide-induced neurotoxicity. Stroke. 32:2001;2370-2375.
52. Klegeris A., McGeer P.L. Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol. Aging. 23:2002;787-794.
53. McGeer P.L., McGeer E.G. Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging. 22:2001;799-809.
54. Weggen S., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 414:2001;212-216.
55. Lu X., et al. Naloxone prevents microglia-induced degeneration of dopaminergic substantia nigra neurons in adult rats. Neuroscience. 97:2000;285-291.
56. Liu B., et al. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J. Pharmacol. Exp. Ther. 293:2000;607-617.
57. Liu Y., et al. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J. Pharmacol. Exp. Ther. 305:2003;212-218.
58. Manna S.K., et al. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J. Immunol. 163:1999;6800-6809.
59. Wang M.J., et al. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur. J. Neurosci. 16:2002;2103-2112.
60. Tikka T., et al. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. J. Neurosci. 21:2001;2580-2588.
61. Yrjanheikki J., et al. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc. Natl. Acad. Sci. U. S. A. 96:1999;13496-13500.
62. Sanchez Mejia R.O., et al. Minocycline reduces traumatic brain injury-mediated caspase-1 activation, tissue damage, and neurological dysfunction. Neurosurgery. 48:2001;1393-1399.
63. Chen M., et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. 6:2000;797-801.
64. Zhu S., et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 417:2002;74-78.
65. Thomas M., et al. Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin. Neuropharmacol. 26:2003;18-23.
66. Delgado M., Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J. 17:2003;944-946.